NCCN 16th Annual Conference

 
 
 

The NCCN 16th Annual Conference took place March 9–13, 2011, in Hollywood, Florida.

 

Will 2nd-gen TKIs supersede imatinib?

Jen Smith Read Article
Published: 03/18/11

 Susan O’Brien, MD
Susan O’Brien, MD

Nilotinib and dasatinib have gained approval as first-line therapy for chronic myelogenous leukemia (CML), and recent studies suggest these agents are more effective than imatinib. However, an expert says we shouldn’t replace imatinib just yet. “The early data with the second-generation TKIs [tyrosine kinase inhibitors] is clearly superior,” said Susan O’Brien, MD, of MD Anderson Cancer Center, in a presentation at the NCCN 16th Annual Conference on March 11. [Read Article]

Studies spur change in FL treatment guidelines

Jen Smith Read Article
Published: 03/17/11

 Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD

New research has prompted the NCCN to change its recommendations regarding first-line and post-remission therapy for follicular lymphoma (FL). The NCCN has upgraded bendamustine plus rituximab from a category 2A to a category 1 recommendation for first-line treatment of FL. In addition, rituximab maintenance and chemotherapy followed by radioimmunotherapy (RIT) have been upgraded from category 2B to category 1 recommendations as post-first-remission therapy. [Read Article]

NCCN advocates CSF prophylaxis for FN

Jen Smith Read Article
Published: 03/15/11

 Jeffrey Crawford, MD
Jeffrey Crawford, MD

The NCCN favors colony-stimulating factors (CSF)—over antibiotics or reducing chemotherapy dose—as prophylaxis for febrile neutropenia (FN). There are a number of studies supporting this recommendation, according to Jeffrey Crawford, MD, head of the NCCN myeloid growth factor committee. He discussed these studies and the NCCN’s recommendations at the NCCN 16th Annual Conference on March 12. [Read Article]

NCCN makes recommendations for PTLD

Jen Smith Read Article
Published: 03/14/11

 Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD

The latest edition of the NCCN guidelines have been expanded to include diagnostic, workup, and treatment information for post-transplant lymphoproliferative disorder (PTLD). PTLD has been added to the guidelines because it is a significant complication of transplant that remains a challenge for physicians, according to Andrew D. Zelenetz, MD, PhD, the head of the NCCN guideline panel for non-Hodgkin’s lymphoma. He discussed PTLD and the new guidelines in a presentation at the NCCN 16th Annual Conference on March 11. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}